AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Castle Biosciences to Present at Three Investor Conferences in September 2025
ByAinvest
Friday, Aug 22, 2025 11:42 pm ET1min read
Castle Biosciences will participate in three investor conferences in September 2025, including a presentation at Baird's Global Healthcare Conference on September 10. The company's management team will also be available for one-on-one meetings at the Wells Fargo and Lake Street Best Ideas Growth Conferences. Investors can coordinate meetings through the respective firms. Castle Biosciences is focused on developing diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma, among other conditions.
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, has announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website. Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.Castle Biosciences aims to improve health through innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma. Additionally, Castle Biosciences has active research and development programs for tests in these and other diseases with high clinical need, including a test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment.
Investors can coordinate meetings with Castle Biosciences' management through Wells Fargo and Lake Street Capital Markets. For more information, please visit www.CastleBiosciences.com and connect with them on LinkedIn, Facebook, X, and Instagram.
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet